Cost of Cancer Care: Issues and Implications
Top Cited Papers
- 10 January 2007
- journal article
- review article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 25 (2), 180-186
- https://doi.org/10.1200/jco.2006.09.6081
Abstract
Medical technology is increasingly costly in most fields of clinical medicine. Oncology has not been spared from issues related to cost, in part resulting from the tremendous scientific progress that has lead to new tools for diagnosis, treatment, and follow-up of our patients. The increasing cost of health care in general (and cancer care in particular) raises complex questions related to its effects on our economy and the citizens of our society. This article reviews the macroeconomic principles and individual behaviors that govern medical spending, and examines how cost disproportionately affects various populations. Our overall goal is to frame debate about health policy concerns that influence the clinical practice of oncology.Keywords
This publication has 50 references indexed in Scilit:
- Cancer Statistics, 2006CA: A Cancer Journal for Clinicians, 2006
- Health Spending Projections Through 2015: Changes On The HorizonHealth Affairs, 2006
- Projecting future drug expenditures—2006American Journal of Health-System Pharmacy, 2006
- Implications of Pharmacogenomics for Drug Development and Clinical PracticeArchives of Internal Medicine, 2005
- High and Rising Health Care Costs. Part 1: Seeking an ExplanationAnnals of Internal Medicine, 2005
- Cancer Statistics, 2005CA: A Cancer Journal for Clinicians, 2005
- U.S. Health Spending Projections For 2004–2014Health Affairs, 2005
- Comparison of Oral Capecitabine Versus Intravenous Fluorouracil Plus Leucovorin as First-Line Treatment in 605 Patients With Metastatic Colorectal Cancer: Results of a Randomized Phase III StudyJournal of Clinical Oncology, 2001
- Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2000
- Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trialThe Lancet, 2000